FDA to review Moderna's mRNA flu vaccine
Digest more
In this episode of Denatured, Jennifer C. Smith-Parker speaks to Erik Digman Wiklund, CEO of Circio and Jacob Becraft, Co-founder and CEO of Strand Therapeutics. They discuss how post-COVID, emerging platforms like circular and logic circuit RNA are expanding the field's therapeutic horizons.
A new addition to the mRNA analytics toolbox enables fast, accurate, and easy-to-use sample analysis while keeping RNA molecules in their native state.
8d
Arcturus Therapeutics Spotlights Inhaled mRNA CF Phase 2b Plan, FDA Talks for OTC Program at Summit
Arcturus Therapeutics (NASDAQ:ARCT) used a presentation at Guggenheim’s 2026 Emerging Outlook Biotech Summit to highlight upcoming milestones for its messenger RNA (mRNA) rare disease pipeline, with C
Pharmaceutical Technology on MSN
RNA-targeting small molecules: A new frontier of drug discovery
With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology advances.
Leveraging its integrated "design-synthesis-quality control" system, Creative Biolabs is overcoming bottlenecks in mRNA
Researchers uncovered how cells coordinate genetic compensation when faulty mRNA is degraded. Small RNA fragments act as sequence “addresses” that recruit ILF3 to activate related backup genes.
According to Precedence Research, the global RNA analysis market size is expected to be worth USD 23.39 billion by 2035, increasing from USD 10.21 billion in 2026, with a strong CAGR of 9.65% from 2026 to 2035.